Table 2.
Comorbidities and co-infections of COVID-19 patients.
| All (n = 267) | Re-positive classification | P value | ||
|---|---|---|---|---|
| No (n = 237) | Yes (n = 30) | |||
| Comorbidities | ||||
| Chronic kidney disease | 5 (2%) | 4 (2%) | 1 (3%) | 0.45 |
| Chronic pulmonary disease | 20 (7%) | 16 (7%) | 4 (13%) | 0.26 |
| Hypertension | 89 (33%) | 77 (32%) | 12 (40%) | 0.41 |
| Diabetes | 45 (17%) | 39 (16%) | 6 (20%) | 0.63 |
| Cardiovascular disease | 28 (10%) | 22 (9%) | 6 (20%) | 0.07 |
| Cerebrovascular disease | 16 (6%) | 14 (6%) | 2 (7%) | 0.7 |
| Malignancy | 7 (3%) | 6 (3%) | 1 (3%) | 0.57 |
| Co-infection | ||||
| Mycoplasma | 17 (6%) | 15 (6%) | 2 (7%) | > 0.99 |
| Chlamydia | 9 (3%) | 7 (3%) | 1 (3%) | > 0.99 |
| Influenza-A/B | 0 | 0 | 0 | NA |